Insilico Medicine
Generative AI platform for end-to-end drug discovery, scientific research & longevity
Enterprise·Technical·Powered by Insilico Medicine (proprietary LLLMs)·API available
Key strengths
End-to-end AI-driven drug discovery pipeline (target ID to clinical)Generative chemistry and biology AI (Chemistry42, Generative Biologics)Disease modeling and target discovery via PandaOmicsClinical trial outcome prediction with inClinicoProprietary Large Language of Life Models (LLLMs)
Enterprise pricing
Cambridge, United States
Founded 2014
No ratings yet
Technical Integration & API Usage
Platform Architecture
Insilico Medicine's Pharma.ai is a modular, cloud-based suite of generative AI tools built on proprietary Large Language of Life Models (LLLMs). Each module is accessible via enterprise licensing and is designed for integration into pharmaceutical R&D pipelines.
Key Modules & Capabilities
- PandaOmics — Multi-omics data ingestion (transcriptomics, proteomics, genomics) for AI-driven target identification and ranking; supports custom disease datasets.
- Chemistry42 — Generative small molecule design engine; accepts target protein inputs and returns optimized lead compounds with predicted ADMET properties.
- Generative Biologics — Extends generative design to antibodies, peptides, and other biologics.
- inClinico — Clinical trial success prediction model; inputs trial parameters (indication, phase, mechanism) and outputs probability-of-success scores.
- Science42:DORA — LLM-based research assistant for scientific literature synthesis, hypothesis generation, and regulatory document drafting.
- Nach01 / MMAI Gym — Benchmarking tools for evaluating AI models on drug discovery tasks.
Licensing & Access
- Available via enterprise licensing — contact the sales team for API credentials and integration documentation.
- Offices in Cambridge MA, Hong Kong, Abu Dhabi, and Shanghai for regional support.